Skip to content

Study · Not a test of the peptide alone · 1999

6 results

Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment.

Herndon DN, Ramzy PI, DebRoy MA, Zheng M, Ferrando AA, Chinkes DL, Barret JP, Wolfe RR, Wolf SE

Annals of surgery1 May 1999Cited by 125 (Europe PMC)

PMID10235530 (opens in a new tab)DOI10.1097/00000658-199905000-00014 (opens in a new tab)PepBankPUB-10235530
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 (mecasermin).

  1. 01HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialEfficacy outcome

    In burned children, IGF‑1/IGFBP-3 did not affect glucose uptake across the leg.

    In plain wordsIn burned children, IGF‑1/IGFBP-3 did not change glucose uptake across the leg.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeGlucose uptake across the leg
    Study

    n = 29

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    IGF-1/IGFBP-3 did not affect glucose uptake across the leg or change substrate utilization.
    2 context sentences
    Summary · context
    Twenty-nine severely burned children were prospectively studied before and after treatment with 0.5, 1, 2, or 4 mg/kg/day IGF-1/IGFBP-3 to determine net balance of protein across the leg, muscle protein fractional synthetic rates, and glucose metabolism.
    Summary · context
    Another group was studied in a similar fashion without IGF-1/IGFBP-3 treatment as time controls.

    In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).

  2. 02HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialEfficacy outcome

    In burned children, IGF‑1/IGFBP-3 did not change substrate utilization.

    In plain wordsIn burned children, IGF‑1/IGFBP-3 did not change how metabolic fuels were used.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeSubstrate utilization
    Study

    n = 29

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    IGF-1/IGFBP-3 did not affect glucose uptake across the leg or change substrate utilization.
    2 context sentences
    Summary · context
    Twenty-nine severely burned children were prospectively studied before and after treatment with 0.5, 1, 2, or 4 mg/kg/day IGF-1/IGFBP-3 to determine net balance of protein across the leg, muscle protein fractional synthetic rates, and glucose metabolism.
    Summary · context
    Another group was studied in a similar fashion without IGF-1/IGFBP-3 treatment as time controls.

    In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).

  3. 03HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialEfficacy outcome

    In burned children, IGF‑1/IGFBP-3 infusion at 1.0 mg/kg/day increased serum IGF‑1.

    In plain wordsIn burned children, the IGF‑1/IGFBP-3 combination increased blood IGF‑1.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseSerum IGF-1 at initial dose
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The infusion of 1.0 mg/kg/day IGF-1/IGFBP-3 increased serum IGF-1, which did not further increase with 2.0 and 4.0 mg/kg/day.
    2 context sentences
    Summary · context
    Twenty-nine severely burned children were prospectively studied before and after treatment with 0.5, 1, 2, or 4 mg/kg/day IGF-1/IGFBP-3 to determine net balance of protein across the leg, muscle protein fractional synthetic rates, and glucose metabolism.
    Summary · context
    Another group was studied in a similar fashion without IGF-1/IGFBP-3 treatment as time controls.

    In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).

  4. 04HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialEfficacy outcome

    In burned children, IGF‑1/IGFBP-3 at 2.0 and 4.0 mg/kg/day did not further increase serum IGF‑1.

    In plain wordsIn burned children, higher doses of IGF‑1/IGFBP-3 did not increase blood IGF‑1 further than the initial dose.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeSerum IGF-1 with dose escalation
    Study

    n: not reported in source

    Comparator
    1.0 mg/kg/day IGF-1/IGFBP-3
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The infusion of 1.0 mg/kg/day IGF-1/IGFBP-3 increased serum IGF-1, which did not further increase with 2.0 and 4.0 mg/kg/day.
    2 context sentences
    Summary · context
    Twenty-nine severely burned children were prospectively studied before and after treatment with 0.5, 1, 2, or 4 mg/kg/day IGF-1/IGFBP-3 to determine net balance of protein across the leg, muscle protein fractional synthetic rates, and glucose metabolism.
    Summary · context
    Another group was studied in a similar fashion without IGF-1/IGFBP-3 treatment as time controls.

    In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).

  5. 05HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialEfficacy outcome

    In burned children, IGF‑1/IGFBP-3 improved net protein balance, with a more pronounced effect in catabolic children.

    In plain wordsIn burned children, IGF‑1/IGFBP-3 improved protein balance, especially in children losing body protein.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseNet protein balance
    Study

    n: not reported in source

    Outcome group
    Muscle injury and repair · Musculoskeletal

    Source sentences

    Summary
    IGF-1/IGFBP-3 treatment at 1 to 4 mg/ kg/day improved net protein balance and increased muscle protein fractional synthetic rates.
    3 context sentences
    Summary · context
    This effect was more pronounced in catabolic children.
    Summary · context
    Twenty-nine severely burned children were prospectively studied before and after treatment with 0.5, 1, 2, or 4 mg/kg/day IGF-1/IGFBP-3 to determine net balance of protein across the leg, muscle protein fractional synthetic rates, and glucose metabolism.
    Summary · context
    Another group was studied in a similar fashion without IGF-1/IGFBP-3 treatment as time controls.

    In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).

  6. 06HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialEfficacy outcome

    In burned children, IGF‑1/IGFBP-3 increased muscle protein fractional synthetic rates, with a more pronounced effect in catabolic children.

    In plain wordsIn burned children, IGF‑1/IGFBP-3 increased muscle protein production, especially in children losing body protein.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseMuscle protein fractional synthetic rate
    Study

    n: not reported in source

    Outcome group
    Muscle injury and repair · Musculoskeletal

    Source sentences

    Summary
    IGF-1/IGFBP-3 treatment at 1 to 4 mg/ kg/day improved net protein balance and increased muscle protein fractional synthetic rates.
    3 context sentences
    Summary · context
    This effect was more pronounced in catabolic children.
    Summary · context
    Twenty-nine severely burned children were prospectively studied before and after treatment with 0.5, 1, 2, or 4 mg/kg/day IGF-1/IGFBP-3 to determine net balance of protein across the leg, muscle protein fractional synthetic rates, and glucose metabolism.
    Summary · context
    Another group was studied in a similar fashion without IGF-1/IGFBP-3 treatment as time controls.

    In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.